PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE
Abstract
Authors
O. Seyhun M. Dinç S. Sevgi F. Aksun O. Basegmez M. Kus
O. Seyhun M. Dinç S. Sevgi F. Aksun O. Basegmez M. Kus
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now